Author

E. Braggio

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

A. M. Abdelrahman· 1 shared A. S. Mansfield· 1 shared A. T. Baker· 1 shared B. M. Nagalo· 1 shared B. Ziccheddu· 1 shared C. K. Stein· 1 shared C. R. Dumbauld· 1 shared C. R. Secreto· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. M. Abdelrahman

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The Vk*MYC Mouse Model recapitulates human multiple myeloma evolution and genomic diversity

F. MAURA, D. G. Coffey, C. K. Stein, E. Braggio, B. Ziccheddu, M. E. Sharik, M. Du, Y. T. Alvarado, C.-X. Shi, Y. X. Zhu, E. W. Meermeier, G. J. Morgan, O. Landgren, L. Bersagel, M. Chesi

The paper develops a Vk*MYC mouse model of multiple myeloma that mirrors human disease progression, genomic diversity, and key molecular features.

bioRxiv · Jul 25, 2023 · PreprintCancer Biology

B Cell Receptor Signaling Drives APOBEC3 Expression Via Direct Enhancer Regulation in Chronic Lymphocytic Leukemia B Cells

Z. Wang, H. Yan, J. C. Boysen, C. R. Secreto, J. Zhong, J. Zhou, H. Gan, C. Yu, E. Braggio, S. L. Slager, S. A. Parikh, N. E. Kay

This study shows BTKi treatment reduces APOBEC3 expression in CLL B cells through enhancer regulation, linking BCR signaling to genomic instability.

bioRxiv · Jul 27, 2021Cancer Biology

Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers

M. Arora, J. M. Bogenberger, A. M. Abdelrahman, J. Yonkus, R. Alva-Ruiz, J. L. Leiting, X. Chen, P. L. Serrano Uson, C. R. Dumbauld, A. T. Baker, S. I. Gamb, J. B. Egan, Y. Zhou, B. M. Nagalo, N. Meurice, , M. J. Borad

This study shows that combining gemcitabine/cisplatin with CDK4/6 inhibitors improves efficacy and reduces toxicity in biliary tract cancers through mechanisms involving autophagy and RRM1 reduction.

bioRxiv · Oct 26, 2020Cancer Biology